Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Takeda Pharmaceutical Company Limited (TAK)

14.35   0.09 (0.63%) 05-16 08:46
Open: 14.3 Pre. Close: 14.26
High: 14.36 Low: 14.25
Volume: 2,355,755 Market Cap: 44,498(M)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.38 - 14.45 14.45 - 14.52
Low: 14.07 - 14.15 14.15 - 14.23
Close: 14.21 - 14.35 14.35 - 14.48

Technical analysis

as of: 2022-05-16 8:21:53 AM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 17.08     One year: 17.6
Support: Support1: 13.92    Support2: 11.58
Resistance: Resistance1: 14.63    Resistance2: 15.06
Pivot: 14.43
Moving Average: MA(5): 14.28     MA(20): 14.46
MA(100): 14.57     MA(250): 15.29
MACD: MACD(12,26): -0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 47.6     %D(3): 35.8
RSI: RSI(14): 46.7
52-week: High: 17.55  Low: 13.17
Average Vol(K): 3-Month: 2,470 (K)  10-Days: 2,882 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TAK ] has closed above bottom band by 38.6%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 16 May 2022
Mufti says 50% tourism in India because of Mughals; Gyanvapi Masjid thi or Qayamat tak rahegi, exhorts Asadudd - Times Now

Mon, 16 May 2022
Gyanvapi Masjid Thi, Aur Qayamat Tak Rahegi: Asaduddin Owaisi | WATCH - India.com

Mon, 16 May 2022
Manhunt for Tak gold shop robber - ฺBangkok Post

Sat, 14 May 2022
Pic Tak: Ruhani Raises the Heat in Black - Mirchi9

Fri, 13 May 2022
Anonymous social app Yik Tak left users' precise locations exposed - Engadget

Thu, 12 May 2022
AajTak launches connected devices stream “Aaj Tak Live News Stream” - BestMediaInfo

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 3.12e+009 (%)
% Held by Institutions 3.14e+009 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 1.29
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 31.5
Profit Margin (%) 13.9
Operating Margin (%) 16.7
Return on Assets (ttm) 2.8
Return on Equity (ttm) 9.4
Qtrly Rev. Growth 7
Gross Profit (p.s.) 2.2
Sales Per Share 3.4
EBITDA (p.s.) 1.07
Qtrly Earnings Growth 1
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 11.03
PEG Ratio 0
Price to Book value 0.45
Price to Sales 4.22
Price to Cash Flow 14.35

Stock Dividends

Dividend 8.6e+006
Forward Dividend 7.81e+006
Dividend Yield 59930300%
Dividend Pay Date 2009-12-14
Ex-Dividend Date 2021-09-28
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.